New Study Unveils Key to Improving Cancer Drug Delivery for Brain Tumors
A groundbreaking study published in ACS Nano on July 1, 2021, titled 'Liposomal Extravasation and Accumulation in Tumors as Studied by Fluorescence Microscopy and Imaging Depend on the Fluorescent Label', has opened new avenues for improving cancer drug-delivery systems, particularly for glioma, a challenging brain tumor to treat.
The research, conducted using breast cancer and brain cancer mouse models, compared the accumulation of two types of fluorescent labels: indocarbocyanine lipids (ICLs) and fluorescent phospholipids (FPLs). Initially, both labels accumulated in tumor blood vessels. However, ICLs continued to spread over a larger tumor area, while FPLs quickly degraded and disappeared. This suggests that different lipids have varying abilities to accumulate in tumors, depending on the fluorescent label used. The team plans to expand their research by studying additional fluorescent lipids and testing them for therapeutic efficacy in various tumor models.
The study's findings pave the way for enhanced cancer drug-delivery systems, especially for hard-to-treat brain tumors like glioma. By understanding the role of fluorescent labels in liposome accumulation, researchers can potentially improve the effectiveness of cancer therapies.
Read also:
- Is it advisable to utilize your personal health insurance in a publicly-funded medical facility?
- Dietary strategies for IBS elimination: Aims and execution methods
- Benefits, suitable dosage, and safety considerations for utilizing pumpkin seed oil in treating an overactive bladder
- Harmful Medical Remedies: A Misguided Approach to Healing
